 Connection
Gregory Schwartz to RNA, Small Interfering
This is a "connection" page, showing publications Gregory Schwartz has written about RNA, Small Interfering.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.862 |
|
|
|
-
Nissen SE, Wang Q, Nicholls SJ, Navar AM, Ray KK, Schwartz GG, Szarek M, Stroes ESG, Troquay R, Dorresteijn JAN, Fok H, Rider DA, Romano S, Wolski K, Rambaran C. Zerlasiran-A Small-Interfering RNA Targeting Lipoprotein(a): A Phase 2 Randomized Clinical Trial. JAMA. 2024 12 17; 332(23):1992-2002.
Score: 0.200
-
Landmesser U, Koenig W, Leiter LA, Raal FJ, Ray KK, Wright RS, Han J, Conde LG, Schwartz GG. Inclisiran in patients with prior myocardial infarction: A post hoc pooled analysis of the ORION-10 and ORION-11 Phase 3 randomised trials. Atherosclerosis. 2023 12; 386:117354.
Score: 0.185
-
Wright RS, Ray KK, Raal FJ, Kallend DG, Jaros M, Koenig W, Leiter LA, Landmesser U, Schwartz GG, Friedman A, Wijngaard PLJ, Garcia Conde L, Kastelein JJP. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. J Am Coll Cardiol. 2021 Mar 09; 77(9):1182-1193.
Score: 0.154
-
Wright RS, Raal FJ, Koenig W, Landmesser U, Leiter LA, Vikarunnessa S, Lesogor A, Maheux P, Talloczy Z, Zang X, Schwartz GG, Ray KK. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial. Cardiovasc Res. 2024 Oct 14; 120(12):1400-1410.
Score: 0.050
-
Leiter LA, Raal FJ, Schwartz GG, Koenig W, Ray KK, Landmesser U, Han J, Conde LG, Wright RS. Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION-9, ORION-10 and ORION-11 Phase 3 randomized trials. Diabetes Obes Metab. 2024 Aug; 26(8):3223-3237.
Score: 0.048
-
Ray KK, Gunn LH, Conde LG, Raal FJ, Wright RS, Gosselin NH, Leiter LA, Koenig W, Schwartz GG, Landmesser U. Estimating potential cardiovascular health benefits of improved population level control of LDL cholesterol through a twice-yearly siRNA-based approach: A simulation study of a health-system level intervention. Atherosclerosis. 2024 04; 391:117472.
Score: 0.047
-
Wright RS, Koenig W, Landmesser U, Leiter LA, Raal FJ, Schwartz GG, Lesogor A, Maheux P, Stratz C, Zang X, Ray KK. Safety and Tolerability of Inclisiran for?Treatment of Hypercholesterolemia in?7 Clinical Trials. J Am Coll Cardiol. 2023 12 12; 82(24):2251-2261.
Score: 0.047
-
Ray KK, Raal FJ, Kallend DG, Jaros MJ, Koenig W, Leiter LA, Landmesser U, Schwartz GG, Lawrence D, Friedman A, Garcia Conde L, Wright RS. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J. 2023 01 07; 44(2):129-138.
Score: 0.044
-
Koenig W, Conde LG, Landmesser U, Leiter LA, Ray KK, Schwartz GG, Wright RS, Han J, Raal FJ. Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials. Cardiovasc Drugs Ther. 2024 Jun; 38(3):493-503.
Score: 0.044
-
Ray KK, Kallend D, Leiter LA, Raal FJ, Koenig W, Jaros MJ, Schwartz GG, Landmesser U, Garcia Conde L, Wright RS. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Eur Heart J. 2022 12 21; 43(48):5047-5057.
Score: 0.044
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|